BIOPHARMX CORPORATION (NYSEMKT:BPMX) Files An 8-K Results of Operations and Financial Condition

BIOPHARMX CORPORATION (NYSEMKT:BPMX) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition

Story continues below

On September 13, 2017, BioPharmX Corporation (“Company”) issued a press release announcing its financial results and certain other information for the quarterly period ended July 31, 2017. A copy of the press release is attached as Exhibit99.1 to this Current Report on Form8-K.

The information in this Item 2.02, including Exhibit99.1 to this Current Report on Form8-K, shall not be deemed to be “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the accompanying Exhibit99.1 shall not be incorporated by reference into any registration statement or other document filed by the Company with the Securities and Exchange Commission, whether made before or after the date of this Current Report on Form8-K, regardless of any general incorporation language in such filing (or any reference to this Current Report on Form8-K generally), except as shall be expressly set forth by specific reference in such filing.

Item 2.02 Financial Statements and Exhibits


BioPharmX Corp Exhibit
EX-99.1 2 v475093_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 BioPharmX Reports Second Quarter 2018 Financial Results Company reports continued progress in clinical programsMENLO PARK,…
To view the full exhibit click here


BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia. Its VI2OLET is an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort and is clinically demonstrated to alleviate the symptoms associated with FBC, including tenderness, aches and swelling. It is developing BPX02, which is an injectable utilizing biologic materials for aesthetic dermatology applications.


BIOPHARMX CORPORATION (NYSEMKT:BPMX) closed its last trading session down -0.040 at 0.300 with 1,387,954 shares trading hands.

An ad to help with our costs